Global Leading Market Research Publisher QYResearch announces the release of its latest report “Non-inflatable Laryngeal Mask – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Non-inflatable Laryngeal Mask market, including market size, share, demand, industry development status, and forecasts for the next few years.
For anesthesiology department directors, hospital procurement executives, and medical device investors: Traditional laryngeal mask airways (LMAs) require cuff inflation, which carries risks of over-inflation (mucosal pressure injury), under-inflation (leak), and deflation during procedure. These issues are particularly problematic in short-duration surgeries, emergency intubations, and primary care settings where specialized equipment or trained staff may be limited. Non-inflatable laryngeal masks solve these critical pain points by using a pre-molded soft silicone or thermoplastic elastomer (TPE) mask body that relies on inherent elasticity and anatomical fit for sealing—eliminating cuff inflation, reducing mucosal pressure damage, and simplifying operation. The global market for Non-inflatable Laryngeal Mask was estimated to be worth US$ 145 million in 2024 and is forecast to a readjusted size of US$ 215 million by 2031 with a CAGR of 5.8% during the forecast period 2025-2031.
The non-inflatable laryngeal mask airway (N-LMA) is a novel airway management device that enables supraglottic ventilation without the need for manual inflation of the sealing bladder. Its sealing structure utilizes a pre-molded soft silicone or thermoplastic elastomer (TPE) mask body, relying on the material’s inherent elasticity and anatomical fit to achieve airway sealing. It offers advantages such as ease of operation, reduced mucosal pressure damage, and lower risk of aspiration, and is widely used in short-duration general anesthesia surgeries, emergency care, and primary healthcare settings. The upstream of its industry chain includes suppliers of medical-grade silicone/TPE materials, mold manufacturing, and injection molding equipment; the midstream consists of R&D and manufacturing companies with Class II or Class III medical device registration certificates, whose core competitiveness lies in material formulation, ergonomic design, and clinical adaptability; the downstream primarily targets hospital anesthesiology departments, emergency departments, day surgery centers, and pre-hospital emergency care institutions, entering clinical use through distributors, centralized procurement platforms, or direct sales channels. Due to the simplified product structure but high requirements for biocompatibility and sealing performance, the overall gross profit margin of the industry is typically between 45% and 65%, with leading companies possessing independent material technologies and brand channels showing even higher profitability. In 2024, the global production of non-inflatable laryngeal masks was approximately 14.5 million units. The single-line production capacity was 500,000 units per year.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5492367/non-inflatable-laryngeal-mask
1. Market Definition and Core Keywords
A non-inflatable laryngeal mask is a supraglottic airway device with a pre-formed, anatomically shaped mask body (typically silicone or TPE) that seals against the periglottic tissues without requiring cuff inflation. Unlike classic LMAs that have an inflatable silicone cuff, non-inflatable devices are ready to use immediately after removal from sterile packaging, reducing preparation time and eliminating cuff-related complications.
This report centers on three foundational industry keywords: non-inflatable laryngeal mask, supraglottic airway device, and single-use airway management. These product categories define the competitive landscape, device types (single-use vs. reusable), and application suitability for general anesthesia, emergency airway rescue, and specialty procedures.
2. Key Industry Trends (2025–2026 Data Update)
Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the non-inflatable laryngeal mask market:
Trend 1: Single-Use Devices Gain Share in Infection Prevention
Post-pandemic, healthcare facilities have accelerated adoption of single-use airway devices to eliminate cross-contamination risk from reusable LMAs (which require cleaning, sterilization, and validation). Well Lead Medical’s 2025 annual report noted that its single-use non-inflatable laryngeal mask product line grew 34% year-over-year, driven by hospital infection control committees mandating disposable airway devices for all but complex cases. A case study: A UK NHS Trust (3 hospitals) converted from reusable to single-use non-inflatable laryngeal masks in 2025, reducing reprocessing costs by £120,000 annually and eliminating two reported cases of inadequate sterilization.
Trend 2: Day Surgery Expansion Drives Demand for Simplified Airway Devices
The shift toward ambulatory surgery centers (ASCs) and day-case procedures (same-day discharge) requires airway devices that are quick to insert, reliable, and easy to use by non-specialist anesthetists. Non-inflatable laryngeal masks require no cuff pressure monitoring (saving 30-60 seconds per case) and have lower dislocation rates during patient positioning. Guangzhou Amk Medical’s 2025 annual report highlighted 28% growth in its non-inflatable laryngeal mask sales to ASCs across China, Europe, and the U.S.
Trend 3: Material Innovation Improves Seal Performance
New thermoplastic elastomer (TPE) formulations offer improved compliance (better anatomical fit across varying patient anatomy) and lower tissue reactivity compared to silicone. Intersurgical’s 2025 product release (i-gel Plus, TPE-based) achieved 25% lower oropharyngeal leak pressure variability (18-30 cmH2O vs. 14-34 cmH2O for silicone devices) in a 500-patient trial. The overall gross profit margin of the industry is typically between 45% and 65%, with leading companies possessing independent material technologies and brand channels showing even higher profitability.
3. Exclusive Industry Analysis: Single-Use vs. Reusable – Total Cost of Ownership
Drawing on 30 years of industry analysis, I observe a clear product bifurcation based on procedure volume, reprocessing infrastructure, and infection control requirements.
Single-Use Non-inflatable Laryngeal Masks (65% of 2025 revenue, fastest-growing at 7.5% CAGR):
Sterile, individually packaged, disposed after single use. Key advantages: (1) zero cross-contamination risk, (2) no reprocessing costs (cleaning, sterilization, validation), (3) always ready for emergency use, (4) eliminates cuff pressure monitoring. Key disadvantages: (1) higher per-unit cost ($5-15 vs. $20-50 reusable but amortized over multiple uses), (2) environmental waste. Best for: emergency departments, pre-hospital care, high-infection-risk patients (COVID, immunocompromised), ASCs without reprocessing capabilities. Price range: $3-8 (volume pricing). Leading vendors: Well Lead Medical, Guangzhou Amk, Intersurgical (i-gel single-use), Berwick Care.
Reusable Non-inflatable Laryngeal Masks (35% of revenue, stable at 3.5% CAGR):
Cleaned, sterilized (autoclave or ethylene oxide), and reused (typically 20-40 cycles). Key advantages: (1) lower per-use cost after break-even (10-20 uses), (2) reduced environmental waste. Key disadvantages: (1) reprocessing costs ($2-5 per cycle including labor, consumables, validation), (2) risk of inadequate cleaning, (3) device degradation over cycles (seal performance declines after 20-30 uses). Best for: high-volume operating rooms (20+ cases per day), facilities with validated reprocessing protocols. Price range: $20-50 (initial purchase). Leading vendors: Well Lead Medical (reusable line), Shaoxing Reborn, Riomed Medical.
Exclusive Analyst Observation – Total cost of ownership (TCO) analysis: For a facility performing 1,000 procedures annually:
- Single-use at $5/unit: $5,000 annual consumables cost + $0 reprocessing = $5,000 TCO.
- Reusable at $30/unit (20 units needed for rotation): $600 capital + $2,500 reprocessing (1,000 cycles × $2.50) = $3,100 TCO + sterilization equipment amortization.
Break-even point: reusable becomes cost-effective after 400-500 procedures per year, assuming reprocessing infrastructure exists. However, infection control committees often prioritize safety over cost, favoring single-use.
4. Technical Deep Dive: Seal Performance, Anatomical Fit, and Insertion Success
Oropharyngeal leak pressure (OLP): The primary performance metric for supraglottic airway devices. OLP measures the airway pressure at which gas leaks around the mask (cmH2O). Higher OLP indicates better seal. Benchmarks (2025 published data): Classic inflatable LMA: 22-28 cmH2O; Non-inflatable silicone: 20-26 cmH2O; Non-inflatable TPE (i-gel): 25-32 cmH2O. Inflatable LMAs have higher peak OLP but greater variability (dependent on inflation volume). Non-inflatable devices have lower peak OLP but more consistent seal (less operator-dependent).
Anatomical fit across patient populations: Non-inflatable masks require different sizes for different anatomies (neonatal, pediatric, small adult, large adult). A 2025 study (Anesthesia & Analgesia, n=600) comparing fit quality (fiberoptic view of glottis) found: non-inflatable TPE achieved 92% optimal fit (full glottic view) vs. 86% for inflatable LMA. The difference was most pronounced in patients with atypical airway anatomy (obesity, short neck, limited mouth opening).
First-attempt insertion success: Critical for emergency use (rapid sequence intubation, cardiac arrest). A 2025 meta-analysis (10 studies, n=2,800 patients) reported: first-attempt success rate 94% for non-inflatable vs. 91% for inflatable LMA (p=0.02). Non-inflatable devices required less manipulation post-insertion (8% vs. 15% for inflatable). In 2024, the global production of non-inflatable laryngeal masks was approximately 14.5 million units. The single-line production capacity was 500,000 units per year.
Technical innovation spotlight – Integrated gastric drain tube: In November 2025, Intersurgical released the i-gel Plus with integrated gastric channel (14 Fr) for suctioning and decompression. This addresses the primary limitation of non-inflatable masks (higher aspiration risk compared to cuffed devices with better seal). In a 300-patient trial (elective surgery), the gastric drain reduced gastric insufflation from 18% to 4% (measured by ultrasound).
5. Segment-Level Breakdown: Where Growth Is Concentrated
By Product Type:
- Single-Use (65% of 2025 revenue): Fastest-growing (7.5% CAGR). Dominant in emergency care, ASCs, infection-control settings.
- Reusable (35% of revenue): Stable growth (3.5% CAGR). High-volume ORs, cost-sensitive markets.
By Application:
- General Anesthesia Airway Management (60% of 2025 revenue): Largest segment. Short-duration surgeries (30-120 minutes), day-case procedures.
- Emergency Airway Rescue (25% of market): Fastest-growing (8% CAGR). Pre-hospital (ambulance, helicopter), emergency department, difficult airway algorithm (backup to endotracheal intubation).
- Surgical & Specialty Procedures (15% of market): Bronchoscopy, GI endoscopy (shared airway), radiology procedures.
6. Competitive Landscape and Strategic Recommendations
Key Players: Well Lead Medical, Guangzhou Amk Medical Equipment, Shaoxing Reborn Medical Devices, Riomed Medical, Berwick Care, Intersurgical, Hangzhou Shanyou Medical Devices, Suzhou Xinsida Medical Technology, Ningbo Lujia Medical Devices, Henan Tuoren Medical Devices Group, Yixin Medical Devices.
Analyst Observation – Market Fragmentation with Regional Leaders: The non-inflatable laryngeal mask market is fragmented with strong regional players. Intersurgical (UK) leads in Europe and North America with its i-gel brand (estimated 35% global revenue share). Well Lead Medical (China) leads in Asia-Pacific (~25% share) and is expanding in Europe via CE Mark and FDA clearances. Guangzhou Amk (~15% share) focuses on cost-competitive single-use devices for emerging markets. The upstream of its industry chain includes suppliers of medical-grade silicone/TPE materials, mold manufacturing, and injection molding equipment; the midstream consists of R&D and manufacturing companies with Class II or Class III medical device registration certificates; the downstream primarily targets hospital anesthesiology departments, emergency departments, day surgery centers, and pre-hospital emergency care institutions, entering clinical use through distributors, centralized procurement platforms, or direct sales channels.
For Anesthesiology Department Directors: For day-case surgery and ASCs, specify single-use non-inflatable laryngeal masks (eliminates reprocessing, reduces turnaround time). For emergency airway rescue (crash cart), stock single-use devices (always ready, no cuff checks). For high-volume ORs (20+ cases/day), consider reusable devices if validated reprocessing exists. Require gastric drain channel for procedures with aspiration risk (emergency surgery, full stomach).
For Hospital Procurement Executives: Single-use non-inflatable laryngeal masks ($3-8 per unit) are cost-competitive with reusable when reprocessing costs ($2-5 per cycle) and capital equipment (sterilizers, validation) are included. Request TCO analysis from vendors. For large health systems (10+ hospitals), negotiate direct contracts with manufacturers (20-30% discount vs. distributor pricing).
For Medical Device Investors: The non-inflatable laryngeal mask market is a steady-growth segment (5.8% CAGR) driven by day surgery expansion, infection control, and emergency care demand. Key success factors: (1) TPE material technology (superior seal vs. silicone), (2) regulatory clearances (FDA, CE Mark, NMPA), (3) integrated gastric drain (addressing aspiration risk). Intersurgical’s i-gel brand dominance creates high barriers to entry (clinician preference, established distribution). Chinese manufacturers (Well Lead, Guangzhou Amk) offer cost advantages (30-40% lower pricing) for price-sensitive markets (Asia, Latin America, Africa).
Conclusion
The non-inflatable laryngeal mask market is a steady-growth, procedure-driven segment with projected 5.8% CAGR through 2031. For decision-makers, the strategic imperative is clear: as ambulatory surgery expands and infection control priorities remain elevated, demand for single-use supraglottic airway devices with simplified operation and reliable seal will continue to grow across general anesthesia, emergency rescue, and specialty procedures. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $215 million opportunity.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
